NewAmsterdam Pharma Company N.V. (NAMS) is an international biopharmaceutical company with a dedication towards the development and commercialization of ground-breaking novel therapies to treat cardiovascular diseases, such as dyslipidemia and NASH. The company takes its name from New Amsterdam Pharma, an innovative reference to the original name of New York, a city known for its spirit of reinvention, transformation, and progress. This spirit is what the company translates into its health operations as it strives to redefine the standards of care for patients with cardiovascular diseases worldwide.
NAMS is founded on a deep understanding of the scientific basis of cardiovascular diseases. Its experienced team is intimately involved in all stages of drug development, from preclinical research to clinical trials. In doing so, they are determined to develop therapies that not only treat and manage diseases, but that also improve patient outcomes and quality of life.
The company's lead program, obicetrapib, is a potent and orally active cholesterol ester transfer protein (CETP) inhibitor. This therapy is currently in Phase 2b clinical trial for the treatment of dyslipidemia, and holds promise for the development of a novel therapeutic for effectively managing cholesterol levels in patients.
NAMS has been successful in attracting significant financial support, including a €160m Series A funding round. The company's goal is to use this capital to expand its current clinical program while conducting further research and development in the cardiovascular and metabolic disease arena. This funding puts NAMS in a strong position to continue its mission of advancing novel candidates through preclinical and clinical development.
In addition to its internal programs, NAMS is also open to strategic partnerships as a means of furthering its reach in the effort to combat cardiovascular diseases. The company actively seeks out and develops collaborations with other entities in the industry that share its mission and commitment to finding innovative solutions for patients.
While Amsterdam, The Netherlands serves as the company's headquarters, NewAmsterdam Pharma Company has a global outlook. It continues to push boundaries, working tirelessly on new treatment possibilities and earning a reputation for both innovation and compassion. NAMS aims to be recognized not just for its top-tier science and pharmaceutical achievements, but also for its unwavering commitment to improving patients' lives. The company is at the forefront of the global fight against cardiovascular diseases, driving progress in treatment and disease management with a perpetual focus on patient well-being.